epstein-barr virus cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2007 (NCT00431210)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- epstein-barr virus cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02822495 | N/A | Jun 30, 2016 | Atara Biotherapeutics |
| NCT00431210 | Phase 1 | Feb 1, 2007 | Harvard University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Atara Biotherapeutics | For profit | 1 | 1 | 1 | 2016 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1